LB Pharmaceuticals Presents Results of Dopamine Receptor Occupancy Studies of LB-102 at ECNP Confere

NEW YORK--(BUSINESS WIRE)--#BrainHealth--LB Pharmaceuticals Inc, (“LB”) a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, announced today that results of PET studies of its lead compound to treat schizophrenia, LB-102, have been presented at t...

Related Keywords

Portugal ,New York ,United States ,Lisbon ,Lisboa ,Andrew Vaino ,Zachary Prensky ,Pharmaceuticals Inc ,Lb Pharmaceuticals ,European College Of Neuropsychopharmacology ,European College ,Chief Scientific Officer ,